DiaMedica Therapeutics (NASDAQ:DMAC) Announces Quarterly Earnings Results, Beats Estimates By $0.01 EPS

DiaMedica Therapeutics (NASDAQ:DMAC) released its quarterly earnings data on Tuesday. The company reported ($0.19) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.01, FiscalAI reports.

Here are the key takeaways from DiaMedica Therapeutics’ conference call:

• Fetal growth restriction program advanced with enrollment completed in the first six-patient cohort at 5 micrograms/kg; top-line results are expected at a September KOL event.
• Late-onset preeclampsia data showed statistically significant, sustained reductions in maternal blood pressure, while mid-dose cohorts also demonstrated meaningful reductions in uterine artery pulsatility, supporting mid-range dose selection for upcoming studies.
• The company expects to begin dosing its Canada early-onset preeclampsia study in Q4 2026 and is pursuing U.K. expansion later this year; a rat pharmacokinetic and pharmacologic study is expected to support a potential U.S. IND submission.
• ReMEDy2 acute ischemic stroke enrollment has exceeded 85% of the 200 patients needed for the interim analysis, which is now anticipated in the first quarter of 2027; enrollment variability in July caused a modest timing shift.
• Cash and short-term investments declined to $43.5 million as of June 30, 2026, from $59.9 million at year-end, although management believes available funds will support operations and planned trials through 2027.

DiaMedica Therapeutics Price Performance

DMAC opened at $6.84 on Thursday. The company has a fifty day moving average price of $6.66 and a 200-day moving average price of $6.93. The firm has a market capitalization of $368.54 million, a P/E ratio of -9.50 and a beta of 1.01. DiaMedica Therapeutics has a one year low of $4.90 and a one year high of $10.42.

DiaMedica Therapeutics News Summary

Here are the key news stories impacting DiaMedica Therapeutics this week:

• Positive Sentiment: HC Wainwright reaffirmed its Buy rating and $12 target price. The firm raised its EPS forecasts for fiscal 2026 through 2028 and for the third and fourth quarters of 2026, indicating expectations for somewhat narrower losses than previously projected. HC Wainwright Reiterates Buy Rating for DiaMedica Therapeutics
• Positive Sentiment: DiaMedica said enrollment in the ReMEDy2 study has surpassed 85% of the 200-patient threshold needed for an interim analysis, which is expected in the first quarter of 2027. The milestone brings a potentially important clinical readout closer and may improve investor focus on the company’s lead therapy, including its preeclampsia opportunity. DiaMedica anticipates ReMEDy2 interim analysis in Q1 2027
• Neutral Sentiment: Recent Q2 2026 earnings-call coverage provided additional management commentary on the company’s pipeline and clinical programs. However, the supplied reports do not indicate a major change to current financial results or guidance. DiaMedica Therapeutics Q2 FY2026 earnings call transcript
• Negative Sentiment: HC Wainwright modestly reduced its FY2029 EPS estimate to a $0.27 loss from a $0.25 loss and its FY2030 estimate to a $0.01 loss from previously projected earnings of $0.04 per share. These revisions suggest profitability may arrive later than previously expected, despite improvements to nearer-term forecasts.

Institutional Investors Weigh In On DiaMedica Therapeutics

Large investors have recently added to or reduced their stakes in the business. Invesco Ltd. grew its position in DiaMedica Therapeutics by 29.9% during the fourth quarter. Invesco Ltd. now owns 18,628 shares of the company’s stock worth $148,000 after buying an additional 4,293 shares in the last quarter. XTX Topco Ltd purchased a new stake in shares of DiaMedica Therapeutics in the 4th quarter valued at about $234,000. Wellington Management Group LLP purchased a new stake in shares of DiaMedica Therapeutics in the 4th quarter valued at about $825,000. Quadrature Capital Ltd bought a new stake in shares of DiaMedica Therapeutics during the 4th quarter valued at about $188,000. Finally, Balyasny Asset Management L.P. purchased a new position in shares of DiaMedica Therapeutics during the fourth quarter worth about $136,000. Institutional investors own 10.12% of the company’s stock.

Wall Street Analysts Forecast Growth

DMAC has been the subject of a number of analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of DiaMedica Therapeutics in a report on Friday, July 17th. Wall Street Zen upgraded DiaMedica Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, June 6th. Finally, HC Wainwright reissued a “buy” rating and set a $12.00 price objective on shares of DiaMedica Therapeutics in a report on Tuesday. Four analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, DiaMedica Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $12.00.

DiaMedica Therapeutics Company Profile

DiaMedica Therapeutics, Inc (NASDAQ: DMAC) is a clinical‐stage biopharmaceutical company focused on developing novel therapies for acute and chronic central nervous system conditions. The company’s lead product candidate, DM199, is a recombinant form of human tissue kallikrein-1 designed to promote neuroprotection and tissue repair through modulation of the kallikrein‐kinin system. DiaMedica’s research and development efforts are centered on translating the regenerative potential of DM199 into effective treatments for disorders with high unmet medical need.

DM199 is being evaluated in acute ischemic stroke, where preclinical studies have demonstrated potential benefits in blood flow restoration, inflammation reduction and neuronal survival.